SEC Form 4 · accession 0001140361-15-010822
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J Mento
Director
Period of report
Mar 5, 2015
Accepted (ET)
Mar 6, 2015 · 6:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 5, 2015 | M | 10,000 | $4.54 | A | 18,771 | D | |
| Common StockF2 | Mar 5, 2015 | S | 6,501 | $18.2955 | D | 12,270 | D | |
| Common StockF3 | holding | — | — | — | 19,944 | I | By Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $4.54 | Mar 5, 2015 | M | 10,000 | D | — | Jun 1, 2020 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.98 to $18.85, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3These shares are held in the Mento Family Trust by Steven J. Mento and Linda A. Mento, Trustees of the Mento Family Trust dated December 29, 1994.
- F4All shares underlying these options are vested and exercisable immediately.